{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:44:04Z","timestamp":1790700244582,"version":"4.1.0"},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,11,28]],"date-time":"2008-11-28T00:00:00Z","timestamp":1227830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Overall survival after allogeneic haematopoietic stem cell transplantation (HSCT) is reduced by the high rate of transplantation\u2010related mortality (TRM), especially because of liver veno\u2010occlusive disease (VOD) or acute graft\u2010vs.\u2010host disease (GVHD) because of the toxicity or inefficacy of busulfan and cyclosporine (CsA), respectively. Results of clinical outcome of previous studies performed to optimize busulfan and CsA therapy by controlling their pharmacokinetic variability by means of maximum <jats:italic>a posteriori<\/jats:italic> (MAP) Bayesian individualization of both drugs are presented. The 90\u2010day VOD\u2010free survival was significantly higher in patients with individualized busulfan doses: 97% vs. 76%. Monitoring CsA trough blood concentrations allowed us to obtain a successful GVHD outcome (mild or moderate GVHD and graft vs. leukaemia effect (GVL) in malignant diseases and no GVHD (in non\u2010malignant ones) in the majority of our patients. Severe GVHD occurred in &lt;5% of patients. TRM in children can be significantly decreased by using population pharmacokinetic models and MAP Bayesian individualization of dose regimens for drugs such as CsA and busulfan.<\/jats:p>","DOI":"10.1111\/j.1472-8206.2008.00652.x","type":"journal-article","created":{"date-parts":[[2008,11,28]],"date-time":"2008-11-28T11:59:25Z","timestamp":1227873565000},"page":"605-608","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["The use of pharmacokinetic models in paediatric onco\u2010haematology: effects on clinical outcome through the examples of busulfan and cyclosporine"],"prefix":"10.1111","volume":"22","author":[{"given":"N.","family":"Bleyzac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,11,28]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1998.tb01507.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318039b478"},{"key":"e_1_2_5_4_2","volume-title":"USC* Pack P.C. Collection Clinical Research Programs","author":"Laboratory of Applied Pharmacokinetics","year":"1995"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703207"},{"key":"e_1_2_5_6_2","volume-title":"Caract\u00e9risation et mod\u00e9lisation de la variabilit\u00e9 pharmacocin\u00e9tique intraindividuelle du busulfan en transplantation de moelle osseuse p\u00e9diatrique","author":"Bertholle V.","year":"2006"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704707"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood.V95.5.1572.005k12_1572_1579","article-title":"Graft versus host disease prophylaxis with low\u2010dose cyclosporine\u2010A reduces the risk of relapse in children with acute leukaemia given HLA\u2010identical sibling bone marrow transplantation: results of a randomised trial","volume":"95","author":"Locatelli F.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.8.3247.3247"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2705"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704213"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704239"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705788"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.10.2962"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3406"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.2002"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1472-8206.2008.00652.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1472-8206.2008.00652.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T10:27:42Z","timestamp":1697020062000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1472-8206.2008.00652.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,28]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1111\/j.1472-8206.2008.00652.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1472-8206.2008.00652.x","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,28]]},"assertion":[{"value":"2008-11-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}